Psychopharmacological Treatment of Emotional Distress
Psychopharmacological Treatment of Emotional Distress: A Randomized Controlled Trial
Icahn School of Medicine at Mount Sinai
80 participants
Mar 13, 2024
INTERVENTIONAL
Conditions
Summary
This is an inpatient four-arm randomized control trial comparing single drug clonazepam (S arm), a two-drug combination clonazepam/olanzapine (D arm), and a three-drug combination clonazepam/olanzapine/buprenorphine (T arm) with treatment as usual (TAU arm) in the treatment of emotional distress, specifically the Suicide Crisis Syndrome (SCS). All participants in experimental arms receive 2-day pulse treatments targeting four out of five of the acute emotional distress symptoms. The primary outcome measure is SCS at discharge and one-month follow-up. The secondary outcome measures include questions about suicidal behaviors associated with emotional distress at a one-month follow-up.
Eligibility
Inclusion Criteria7
- Patient admitted to an inpatient unit and ruled in for SCS diagnosis using SCS-C
- Willing to stay in the hospital voluntarily, if medically necessary, for at least 4 days after enrolling in the study.
- Patient admitted to an inpatient unit as a result of a recent (i.e., past-month) suicide attempt, as defined by the C-SSRS (Columbia Suicide Rating Scale).
- Admitted to an inpatient unit in the last 36 hrs.
- Able to understand the nature and the substance of the consent form.
- Currently domiciled.
- Able and willing to provide verifiable contact information for follow-up.
Exclusion Criteria9
- Intellectual disability, cognitive impairment, or linguistic limitation precluding understanding of the consent or research questions.
- Past adverse reactions to clonazepam, olanzapine, or buprenorphine
- Past history of opiate or benzodiazepine use d/o in the last 2 years
- On agonist therapy for opiate addiction
- Ongoing treatment with clonazepam or olanzapine.
- Significant medical or neurological disease or possible delirium that might interfere with study participation or capacity to provide informed consent.
- Receiving involuntary treatment in psychiatric unit
- Clinical suspicion of malingering by a CP.
- Undomiciled.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
0.5 mg twice a day (1 mg a day)
2.5 mg once a day of Olanzapine
2 mg once a day of Buprenorphine
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06133114